Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $130.00

Halozyme Therapeutics (NASDAQ:HALO) had its target price upped by TD Cowen from $105.00 to $130.00 in a research note released on Tuesday morning,Benzinga reports. TD Cowen currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also commented on the company. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Citizens Jmp lifted their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Finally, Wells Fargo & Company lifted their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $96.50.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $121.51 on Tuesday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $122.33. The stock has a market cap of $13.79 billion, a price-to-earnings ratio of 23.70, a P/E/G ratio of 0.44 and a beta of 0.88. The company’s fifty day moving average is $108.68 and its 200 day moving average is $84.66.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. Halozyme Therapeutics’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts forecast that Halozyme Therapeutics will post 8.31 EPS for the current year.

Insider Activity

In related news, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director owned 40,418 shares in the company, valued at $4,154,970.40. The trade was a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 5,230 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $108.54, for a total transaction of $567,664.20. Following the transaction, the director owned 53,609 shares in the company, valued at $5,818,720.86. The trade was a 8.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,852 shares of company stock worth $13,538,046 in the last quarter. 2.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Mather Group LLC. boosted its position in shares of Halozyme Therapeutics by 48.9% during the 3rd quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 136 shares in the last quarter. Signal Advisors Wealth LLC acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $850,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $232,000. Cooper Investors PTY Ltd. increased its position in Halozyme Therapeutics by 19.8% in the 3rd quarter. Cooper Investors PTY Ltd. now owns 65,933 shares of the biopharmaceutical company’s stock valued at $7,279,000 after buying an additional 10,910 shares in the last quarter. Finally, NorthCrest Asset Manangement LLC increased its position in Halozyme Therapeutics by 27.7% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 57,661 shares of the biopharmaceutical company’s stock valued at $6,333,000 after buying an additional 12,511 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks upgraded HALO from “Hold” to “Strong Buy,” providing a fresh endorsement of the company’s growth outlook and potentially attracting additional buying interest.
• Positive Sentiment: TD Cowen raised its price target to $130 from $105 while maintaining a Buy rating. The higher target suggests analysts see further appreciation potential after the stock’s recent rally. TD Cowen Forecasts Strong Price Appreciation for Halozyme Therapeutics Stock
• Positive Sentiment: FDA approval of Roche’s Tecentriq Hybreza for stage III mismatch-repair-deficient colon cancer expands the commercial opportunity for a Halozyme-enabled product. The approval could support future royalty revenue, with clinical data showing a 50% reduction in recurrence or death risk versus chemotherapy alone. Partner-drug approval, patent win and bullish analyst call
• Positive Sentiment: A Dutch court injunction blocking Merck’s Keytruda SC manufacturing and sales in several European markets reduces a competitive and intellectual-property overhang for Halozyme’s technology.
• Positive Sentiment: Zacks highlighted Halozyme’s solid growth characteristics as a reason growth investors should not overlook the stock. Three reasons growth investors should not overlook Halozyme
• Neutral Sentiment: Institutional positioning was mixed: 354 investors added HALO shares while 266 reduced their holdings. This indicates continued interest but also some profit-taking and portfolio rebalancing.
• Negative Sentiment: Insider activity was a potential cautionary signal, with executives reporting sales and no purchases over the past six months. These transactions may reflect profit-taking rather than a change in business fundamentals, but they could temper sentiment after the strong advance.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.